The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of ...

The US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy ... “Our goal is to ensure that Lilly antibody treatments are available to patients who need them, no matter ...

This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.

Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

The "Biopharmaceutical Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Global Biopharmaceutical ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent ...

Celldex's lead candidate is barzolvolimab, a monoclonal antibody that targets KIT ... Novo Nordisk (NVO) and Eli Lilly (LLY).

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...